Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Monoclonal antibodies targeting programmed cell death 1/programmed cell death ligand 1
(PD-1/PD-L1) immune checkpoints have improved the treatments of cancers. However, not …
(PD-1/PD-L1) immune checkpoints have improved the treatments of cancers. However, not …
Platinum derivatives effects on anticancer immune response
Along with surgery and radiotherapy, chemotherapeutic agents belong to the therapeutic
arsenal in cancer treatment. In addition to their direct cytotoxic effects, these agents also …
arsenal in cancer treatment. In addition to their direct cytotoxic effects, these agents also …
SETDB1 tumour suppressor roles in near-haploid mesothelioma involve TP53
M Xu, Y Tu, W Bi, MZ Lundberg, I Klooster… - British Journal of …, 2023 - nature.com
Background Mutational inactivation of the SETDB1 histone methyltransferase is found in a
subset of mesothelioma, particularly in cases with near-haploidy and TP53 mutations …
subset of mesothelioma, particularly in cases with near-haploidy and TP53 mutations …
The immune microenvironment of malignant pleural mesothelioma: A literature review
AL Désage, G Karpathiou, M Peoc'h, ME Froudarakis - Cancers, 2021 - mdpi.com
Simple Summary Malignant pleural mesothelioma is a rare and aggressive tumour,
associated with asbestos exposure. Current therapeutic approaches for malignant …
associated with asbestos exposure. Current therapeutic approaches for malignant …
The search for an interesting partner to combine with PD-L1 blockade in mesothelioma: focus on TIM-3 and LAG-3
Simple Summary Malignant pleural mesothelioma is an aggressive cancer most commonly
associated with asbestos exposure. Its prognosis is very poor, and the current treatments …
associated with asbestos exposure. Its prognosis is very poor, and the current treatments …
Novel and future treatment options in mesothelioma: a systematic review
D Štrbac, V Dolžan - International journal of molecular sciences, 2022 - mdpi.com
Mesothelioma is a rare tumor, frequently associated with asbestos exposure, arising from
pleura and peritoneum. Traditionally, diagnosis and treatment have been difficult in a clinical …
pleura and peritoneum. Traditionally, diagnosis and treatment have been difficult in a clinical …
TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, preventive, and personalized medicine
S Zhang, X Wan, M Lv, C Li, Q Chu, G Wang - EPMA Journal, 2022 - Springer
Background Pancreatic cancer presents extremely poor prognosis due to the difficulty of
early diagnosis, low resection rate, and high rates of recurrence and metastasis. Immune …
early diagnosis, low resection rate, and high rates of recurrence and metastasis. Immune …
Programmed death-ligand 2 (PD-L2) expression in bladder cancer
Objective Immune checkpoint blockade is an optional and effective therapy for bladder
cancer. The present study was aimed to investigate the expression of programmed death …
cancer. The present study was aimed to investigate the expression of programmed death …
Recent advances of immune checkpoint inhibition and potential for (Combined) TIGIT blockade as a new strategy for malignant pleural mesothelioma
S Rovers, A Janssens, J Raskin, P Pauwels… - Biomedicines, 2022 - mdpi.com
Malignant pleural mesothelioma (MPM) is a fatal cancer type that affects the membranes
lining the lungs, and is causally associated with asbestos exposure. Until recently, the first …
lining the lungs, and is causally associated with asbestos exposure. Until recently, the first …
[HTML][HTML] Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
The introduction of immune checkpoint inhibitors (ICIs) in non-oncogene addicted non-small
cell lung cancer (NSCLC) has revolutionized the treatment scenario and led to a meaningful …
cell lung cancer (NSCLC) has revolutionized the treatment scenario and led to a meaningful …